Oncoheal Healthcare LLP

Novoeight 250IU injection is an antihemophilic medicine in the class of miscellaneous coagulation modifiers containing the active ingredient Factor VIII. It is used to treat and prevent bleeding in individuals with hemophilia A, a genetic disorder caused by a deficiency or dysfunction of factor VIII, a clotting protein in the blood.

This drug is contraindicated in individuals with known hypersensitivity or allergy to it or its component. Stop taking this tablet and contact your doctor immediately if you develop a rash or skin symptoms. The use of this drug increases the cardiovascular risk. It is highly advised to discuss with your physician if you have any existing heart disease condition before initiating the treatment with Novoeight 250IU Injection. A central venous access device (CVAD) may sometimes be required to administer this drug treatment. It's important to consider the risks associated with CVAD-related complications, including local infections, bacteremia (bacterial infection in the bloodstream), and catheter site thrombosis (blood clot formation at the catheter site). Proper care and monitoring should be exercised to minimize these risks.